References
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. General considerations for clinical trials; 1997. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf. Accessed March 10, 2019.
- Food and Drug Administration. Guidance for Industry and Review Staff Target Product Profile – A Strategic Development Process Tool. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080593.pdf. Accessed March 10, 2019.
- Food and Drug Administration. Critical path initiative. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/critical-path-initiative. Accessed August 05, 2019.
- Hwang TJ, Darrow JJ, Kesselheim AS. The FDA’s expedited programs and clinical development times for novel therapeutics, 2012-2016. JAMA. 2017;318(21):2137–2138. doi:10.1001/jama.2017.14896
- The European Parliament and the Council of the European Union. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 Laying Down Community Procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Available from: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF. Accessed March 10, 2019.
- Garvin DA. Building a learning organization. Harv Bus Rev. 1993;71(4):78–79. Available from: https://hbr.org/1993/07/building-a-learning-organization. Accessed March 10, 2019.
- Porter ME. Competitive Advantage: Creating and Sustaining Superior Performance. New York: Free Press; 1985.
- Porter ME. Towards a dynamic theory of strategy. Strategic Manag J. 1991;12:95–117. doi:10.1002/(ISSN)1097-0266.
- Papathanasiou P, Brassart L, Blake P, et al. Transparency in drug regulation: public assessment reports in Europe and Australia. Drug Discov Today. 2016;21:1806–1813.
- Van Luijn JC, Stolk P, Gribnau FW, et al. Gap in publication of comparative information on new medicines. Br J Clin Pharmacol. 2008;65(5):716–722. doi:10.1111/j.1365-2125.2007.03092.x
- Eichler HG, Abadie E, Breckenridge A, et al. Open clinical trial data for all? A view from regulators. PLoS Med. 2012;9(4):e1001202. doi:10.1371/journal.pmed.1001202
- European Medicines Agency. Access to clinical-trial data and transparency. Workshop report. Available from: https://www.ema.europa.eu/en/documents/report/access-clinical-trial-data-transparency-workshop-report_en.pdf. Accessed March 11, 2019.
- European Medicines Agency. European Medicines Agency Policy on Publication of Clinical Data for Medicinal Products for Human Use. Available from: https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use_en.pdf. Accessed March 10, 2019.
- European Medicines Agency. Background to Clinical Data Publication Policy. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/clinical-data-publication/background-clinical-data-publication-policy. Accessed March 11, 2019.
- European Medicines Agency. Clinical Data Publication. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/clinical-data-publication. Accessed March 11, 2019.
- European Medicines Agency. Clinical Data. Available from: https://clinicaldata.ema.europa.eu/web/cdp/home. Accessed March 11, 2019.
- European Medicines Agency. External Guidance on the Implementation of the European Medicines Agency Policy on the Publication of Clinical Data for Medicinal Products for Human Use: Version 1.1. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data_en-2.pdf. Accessed March 11, 2019.
- European Medicines Agency. External Guidance on the Implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use: version 1.2. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data_en.pdf. Accessed March 11, 2019.
- European Medicines Agency. External Guidance on the Implementation of the European Medicines Agency Policy on the Publication of Clinical Data for Medicinal Products For Human Use: Version 1.3. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data_en-1.pdf. Accessed March 11, 2019.
- Henry-Eude SA. European Medicines Agency. EMA update on Clinical Data Publication (CDP); 2018 Available from: https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-update-clinical-data-publication-cdp-anne-sophie-henry-eude_en.pdf. Accessed March 11, 2019.
- Ross JS, Waldstreicher J, Bamford S, et al. Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Sci Data. 2018;5:180268. doi:10.1038/sdata.2018.187
- So D, Knoppers BM. Ethics approval in applications for open-access clinical trial data: an analysis of researcher statements to clinicalstudydatarequest.com. PLoS One. 2017;12(9):e0184491. doi:10.1371/journal.pone.0184491
- Billiones R, Schneider A. Navigating the EMA clinical data website. Med Writing. 2018;27(2):19–21.
- Moen RD, Norman CL; Circling back. Clearing up myths about the Deming cycle and seeing how it keeps evolving. Qual Prog. 2010. Available from: http://www.apiweb.org/circling-back.pdf. Accessed March 11, 2019.
- Maylor H. Project Management. 2nd ed. London: Financial Times Pitman Publishing; 1999.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Revision of M4E guideline on enhancing the format and structure of benefit-risk information in ICH Efficacy -– E4E(R2); 2016. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4E_R2_Efficacy/M4E_R2__Step_4.pdf. Accessed March 11, 2019.
- Devaux SA. The drag efficient. The missing quantification of time on the critical path. Defense AT&L. 2012, Available from: https://web.archive.org/web/20130313022307/http://www.dau.mil/pubscats/ATL%20Docs/Jan_Feb_2012/Devaux.pdf. Accessed March 11, 2019.
- European Medicines Agency. EMA/CHMP/ICH/309348/2008 ICH guideline E2F on development safety update report September 2011. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-26.pdf. Accessed March 11, 2019.
- Ananthakrishnan R, Gona P. Pharmacological modeling and biostatistical analysis of a new drug. Open Access J Clin Trials. 2010;2:59–82. doi:10.2147/OAJCT.S9290
- Hung H. Considerations in adapting clinical trial design. J Formos Med Assoc. 2008;107(12 Suppl):14–18. doi:10.1016/S0929-6646(09)60004-8
- Burgess LJ, Terblanche M. The future of the pharmaceutical, biological and medical device industry. Open Access J Clin Trials. 2011;3:45–50.
- Kondo H, Hata T, Ito K, et al. The current status of Sakigake designation in Japan, PRIME in the European Union, and breakthrough therapy designation in the United States. Ther Innov Regul Sci. 2017;51(1):51–54.
- Vu HH, Pariser AR. Pre-Investigational new drug meetings with the FDA: evaluation of meeting content and characteristics of applications for new drug and biologic products. Ther Innov Regul Sci. 2015;49(3):434–442.
- WHO Primary Registries. Available from: http://www.who.int/ictrp/network/primary/en/. Accessed March 11, 2019.
- Drugs@FDA: FDA approved drug products. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed March 11, 2019.
- van Der Steen N, Caparello C, Rolfo C, et al. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong. Onco Targets Ther. 2016;9:6065–6074. doi:10.2147/OTT.S97644
- Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep. 2004. doi:10.1038/sj.embor.7400236.
- Hobbs BP, Barata PC, Kanjanapan Y, et al. Seamless designs: current practice and considerations for early-phase drug development in oncology. J Natl Cancer Inst. 2019;111(2):118–128. doi:10.1093/jnci/djy196
- Miseta E. Acceptable risk reduces clinical development time. Clin Leader. 2018, Available from: https://www.clinicalleader.com/doc/acceptable-risk-reduces-clinical-development-time-0001. Accessed March 11, 2019.
- Booth B. Painful truth: the successful failure of a biotech startup. Forbes. 2017, Available from: https://www.forbes.com/sites/brucebooth/2017/11/17/painful-truth-successful-failure-of-a-biotech-startup/#619f89b3d025. Accessed March 11, 2019.